Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
The average reduction in liver fat reached 86%, a figure that far exceeds the modest to moderate reductions seen with semaglutide and tirzepatide
Retatrutide (research phase) Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors
GLP-1s may not be suitable for people who: Have a history of pancreatitis Have certain thyroid conditions (e.g., medullary thyroid cancer) Are pregnant or breastfeeding (depending on the specific medication) Have severe gastrointestinal conditions, like gastroparesis GLP-1 receptor agonists, including Tirzepatide, have been shown to lead to significant weight loss, with many people losing 10-15% of their body weight over time
GLP-1 meds slow down how quickly your stomach empties
USA 105 , 877882 (2008) Lebon, G
The right choice depends on your health goals, medical history, and insurance coverage
US$ 23.02
US$ 24.45
US$ 26.46
US$ 23.42
US$ 20.05
